These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9530549)

  • 41. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fortovase approved: new saquinavir formulation.
    James JS
    AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New formulation of saquinavir enters clinical trials.
    Bowers M
    BETA; 1996 Sep; ():3. PubMed ID: 11363885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amprenavir: a review of its clinical potential in patients with HIV infection.
    Noble S; Goa KL
    Drugs; 2000 Dec; 60(6):1383-410. PubMed ID: 11152018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual protease inhibitor therapy.
    HIV Hotline; 1998 Mar; 8(1):12. PubMed ID: 11365354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.
    Perry CM; Faulds D
    Drugs; 1997 Apr; 53(4):657-80. PubMed ID: 9098665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of treatment failure during highly active antiretroviral therapy (racing trial).
    Masuhr A; Mueller M; Simon V; Zwingers T; Kurowski M; Jessen H; Lauenroth-Mai E; Moll A; Schranz D; Moecklinghoff C; Arastéh K
    Eur J Med Res; 2002 Aug; 7(8):341-6. PubMed ID: 12204841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New saquinavir formula more potent than original.
    Bartnof HS
    BETA; 1997 Sep; ():45. PubMed ID: 11364701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Saquinavir update.
    Treat Rev; 1997 Aug; (No 25):6. PubMed ID: 11364616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission.
    Vithayasai V; Moyle GJ; Supajatura V; Wattanatchariya N; Kanshana S; Sirichthaporn P; Dabtham K; Somburanasin P; Chantawuttinan T; Hill AM; Hawkins D
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):410-2. PubMed ID: 12138347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
    Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K
    Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763
    [No Abstract]   [Full Text] [Related]  

  • 56. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.
    Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E
    HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.